Document is current
Any future updates will be listed below
-
Authors
,
Zettergren, Anna http://orcid.org/0000-0002-7182-8417
Lord, Jodie
Ashton, Nicholas J.
Benedet, Andrea L.
Karikari, Thomas K.
Lantero Rodriguez, Juan
Snellman, Anniina
Suárez-Calvet, Marc
Proitsi, Petroula
Zetterberg, Henrik
Blennow, Kaj
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2017-00915, 2018-02532)
Alzheimer's Drug Discovery Foundation (RDAPB-201809-2016615, 201809-2016862)
Alzheimerfonden (AF-742881, AF-930627, AF-930582)
Hjärnfonden (FO2017-0243, FO2020-0240)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
European Research Council (681712)
- License Information
-
More Information
Article History
Received: 28 August 2020
Accepted: 16 December 2020
First Online: 8 January 2021
Ethics approval and consent to participate
: Regional ethical committees of all institutions included in ADNI approved of the study and all subjects have provided informed consent.
: Not applicable.
: KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.
